الفهرس Only 14 pages are availabe for public view
 |  | from | 194 |  |  |
| | | from | 194 | | |
Abstract
The adipose tissue is currently considered as a hormonally active system in the control of metabolism and not only as a store of excess energy.
ADPN is one example of the substances secreted from adipose tissues that possesses antihyperglycemic, anti-atherogenic and antiinflammatory properties (Trayhurn & Beattie, 2001).
ADPN circulates at relatively high concentration (0.5-30 μg/ml) in the serum.
This concentration is about 1000-fold higher than the concentration of most other hormones such as leptin and insulin. In fact,ADPN accounts for 0.01 % of total human plasma proteins and is the most abundant adipose tissue protein (Sianko et al., 2005).
Kidney function is an important determinant of circulating levels of ADPN (Becker et al., 2005), and levels of this protein are markedly elevated in kidney failure (Becker et al., 2005). Data on the relationship between ADPN and outcomes in patients with chronic kidney disease(CKD) are sparse. Low ADPN levels were associated with increased risk for cardiovascular disease (CVD) events in one study of hemodialysis patients (Becker et al., 2002).
Chronic renal failure is a widely recognized cause of non-thyroidal illness (Lim 2001). Low levels of the active form of the thyroid hormone,free triiodothyronine (FT3), are the hallmark of this disturbance. It is interpreted as a finalistic adaptation aimed at maintaining energy balance and minimizing protein wasting. Approximately one fourth of patients with ESRD display low FT3, thyroid dysfunction being an emerging problem also in patients with moderate to severe chronic kidney diseases(Lo et al., 2005).
The aim of this work is to study serum ADPN - thyroid hormones levels inter-relationship in patients with chronic renal failure treated conservatively and in those maintained on chronic hemodialysis.